| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 · Established CVD | Ph 3 | Completed | 635 | Jun 2025 | 4 | |
| REWINDResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | Dulaglutide Cardiovascular disease, Type 2 diabetes | HbA1c ≤9.5% | Ph 3 | Completed | 300 | Aug 2018 | 18 | results |
| SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Dulaglutide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 209 | Apr 2017 | 13 | results |
| AWARD-11A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 208 | May 2019 | 3 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| NCT01191268A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) | Dulaglutide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 101 | Feb 2012 | 4 | results |
| NCT00734474A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin | Dulaglutide Type 2 diabetes | BMI 25-40 | Ph 2/3 | Completed | 99 | Jun 2011 | 7 | results |
| NCT01126580A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) | Dulaglutide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 91 | Nov 2011 | 4 | results |
| AWARD-1A Study in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Exenatide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 89 | Nov 2011 | 3 | results |
| AWARD-7A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) | Dulaglutide Chronic kidney disease, Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 89 | Jun 2016 | 2 | results |
| AWARD-2A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) | Dulaglutide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 78 | May 2012 | 3 | results |
| NCT01149421A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 76 | Sep 2011 | 1 | results |
| NCT02973100A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy | Dulaglutide Type 2 diabetes | BMI ≥25 | Ph 2 | Completed | 66 | Jul 2017 | — | results |
| AWARD-PEDSA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Dulaglutide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 61 | Jun 2021 | 2 | results |
| AWARD-6A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes | Dulaglutide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 57 | Nov 2013 | 3 | results |
| NCT06739122A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Dulaglutide Obesity / overweight, Type 2 diabetes | Age 10-17 | Ph 3 | Recruiting | 51 | Dec 2027 | — | |
| NCT03131687A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Tirzepatide Type 2 diabetes | BMI 23-50 | Ph 2 | Completed | 49 | Aug 2018 | 4 | results |
| NCT00791479Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 23-40 | Ph 2 | Completed | 46 | Jan 2010 | 1 | results |
| SURPASS J-monoA Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Dulaglutide, Tirzepatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 46 | Mar 2021 | 6 | results |
| AMPLITUDE-DEfficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin | Dulaglutide, Efpeglenatide Type 2 diabetes | — | Ph 3 | Terminated | 45 | Oct 2020 | — | results |
| AWARD-JPNA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥18.5 | Ph 3 | Completed | 44 | Oct 2022 | — | results |
| NCT05048719A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Orforglipron Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 44 | Sep 2022 | 2 | results |
| NCT04867785A Study of LY3437943 in Participants With Type 2 Diabetes | Dulaglutide, Retatrutide Type 2 diabetes | HbA1c 7-10.5% | Ph 2 | Completed | 43 | Jul 2022 | 2 | results |
| AWARD-10A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 41 | Feb 2017 | 2 | results |
| AWARD-9A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes | Dulaglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 40 | Oct 2015 | 2 | results |
| SURPASS-SWITCHA Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) | Dulaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 38 | Jul 2024 | 2 | results |
| PRECIDENTDPREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Cardiovascular disease, Type 2 diabetes | Established ASCVD/CKD | Ph 4 | Recruiting | 36 | Mar 2029 | 1 | |
| EGOA Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus | Dulaglutide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 2 | Completed | 34 | Jan 2009 | — | results |
| PIONEER 10Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Dulaglutide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 34 | Jul 2018 | 5 | results |
| AWARD-8Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) | Dulaglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 31 | Dec 2014 | 1 | results |
| AWARD-CHN1A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI 19-35 | Ph 3 | Completed | 30 | Aug 2014 | 5 | results |
| AWARD-CHN2A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI 19-35 | Ph 3 | Completed | 30 | Aug 2014 | 8 | results |
| AWARD-CHN3A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 19-35 | Ph 3 | Completed | 27 | Apr 2022 | — | results |
| NCT02750410A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 18.5-35 | Ph 4 | Completed | 25 | Jun 2018 | 2 | results |
| NCT01584232A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI 18.5-35 | Ph 3 | Completed | 15 | Jul 2013 | 1 | results |
| NCT01468181A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI 18.5-35 | Ph 3 | Completed | 14 | Dec 2013 | — | results |
| NCT01558271A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 14 | Oct 2013 | 2 | results |
| NCT03724981A Study Comparing the Dulaglutide Pen and the Semaglutide Pen | Dulaglutide, Semaglutide Type 2 diabetes | — | Ph 4 | Completed | 14 | Apr 2019 | 1 | results |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | — | Completed | 11 | Nov 2023 | 14 | |
| REALISTResearching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) | Dulaglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | BMI ≤40 | Ph 4 | Unknown | 9 | Sep 2023 | — | |
| DIAMOND GLP1Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes | Dulaglutide Type 1 diabetes | BMI ≤30 | Ph 2 | Completed | 7 | Feb 2021 | — | |
| NCT05659537A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India | Dulaglutide Type 2 diabetes | BMI ≥23 | Ph 4 | Completed | 7 | Jan 2024 | — | results |
| NCT01001104A Study of LY2189265 in Japanese Patients With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI ≥18.5 | Ph 2 | Completed | 6 | Dec 2010 | — | results |
| GLP-1REWINGLP-1 REceptor Agonists and Real World EvIdeNce | Dulaglutide, Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Unknown | 6 | Feb 2019 | 6 | |
| BESTMEDBESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | — | Unknown | 5 | Jun 2024 | 3 | |
| NCT05377333A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 27-45 | Ph 1 | Completed | 5 | Nov 2023 | — | |
| NCT04143802A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Dulaglutide, Retatrutide Type 2 diabetes | BMI 23-50 | Ph 1 | Completed | 4 | Dec 2020 | 1 | |
| NCT05005741The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. | Beinaglutide, Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI 24-35 | Ph 4 | Unknown | 4 | Dec 2023 | — | |
| GLUMINSGLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery | Dulaglutide Perioperative / gastric aspiration risk | — | Ph 4 | Recruiting | 3 | Dec 2028 | 2 | |
| EPHIC-DIA2Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | Dulaglutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Active, not recruiting | 3 | Jun 2026 | — | |
| NCT01324388A Study of the Effect of LY2189265 on Two Blood Pressure Drugs | Dulaglutide Healthy volunteers, Hypertension | BMI 18.5-40 | Ph 1 | Completed | 3 | Aug 2011 | — | results |
| NCT01408888A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 23-40 | Ph 1 | Completed | 3 | Apr 2012 | — | results |
| NCT03743025Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients | Dulaglutide Cardiovascular disease, Obesity / overweight, Perioperative / gastric aspiration risk | BMI ≥25 | Ph 4 | Terminated | 3 | May 2023 | — | results |
| NCT04515576A Study of LY3493269 in Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | BMI 23-50 | Ph 1 | Completed | 3 | Mar 2021 | — | results |
| NCT07156539A Phase 3 Study of HS-20094 in Patients With T2DM | Dulaglutide Type 2 diabetes | BMI ≥23 | Ph 3 | Not yet recruiting | 2 | Mar 2027 | — | |
| NCT01253304A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment | Dulaglutide Healthy volunteers, Hepatic impairment | BMI 19-40 | Ph 1 | Completed | 2 | Nov 2011 | — | results |
| NCT02759107A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Dulaglutide, Tirzepatide Healthy volunteers, Type 2 diabetes | BMI ≥18.5 | Ph 1 | Completed | 2 | Jun 2017 | 1 | results |
| NCT04862234Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients | Dulaglutide Obesity / overweight, Perioperative / gastric aspiration risk, Prediabetes / glucose intolerance | BMI ≥30 | Ph 4 | Terminated | 2 | Jun 2023 | — | results |
| NCT06533527Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Dulaglutide, Liraglutide, Semaglutide, Tirzepatide Perioperative / gastric aspiration risk | — | Ph 4 | Completed | 2 | May 2025 | 4 | results |
| NCT07319286Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus | Dulaglutide Reproductive / infertility, Type 1 diabetes | HbA1c ≥7% | Ph 1/2 | By invitation | 2 | Apr 2026 | 1 | |
| NCT04641312A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes | Dulaglutide Healthy volunteers, Type 2 diabetes | BMI 18.5-35 | Ph 1 | Completed | 2 | Dec 2021 | — | |
| NCT04731272GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | Dulaglutide Cystic Fibrosis, Diabetes (other / unspecified), Prediabetes / glucose intolerance | HbA1c ≤8% | Ph 2 | Recruiting | 2 | Jun 2027 | — | |
| NCT06148649Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus | Dulaglutide, HEC88473 Type 2 diabetes | HbA1c 7.5-10.5% | Ph 2 | Completed | 2 | Feb 2025 | — | |
| NCT01511393An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | Dulaglutide, Exenatide, Liraglutide, Semaglutide Oncology | — | — | By invitation | 1 | Dec 2039 | 1 | |
| CER-4-T2DComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | — | |
| NCT06257966A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin | Dulaglutide, Exenatide Type 2 diabetes | BMI 18.5-35 | Ph 3 | Active, not recruiting | 1 | Oct 2026 | — | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| NCT06581120GLP_1 RA Ultrasound Study | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Perioperative / gastric aspiration risk, Type 2 diabetes | BMI ≥35 | — | By invitation | 1 | Jul 2026 | — | |
| NCT06611904The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria | Dulaglutide Chronic kidney disease, Type 2 diabetes | HbA1c 7-10% | Not applicable | Active, not recruiting | 1 | Feb 2022 | 3 | |
| METSAFEMetabolic Surgery for Atrial Fibrillation Elimination | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Atrial fibrillation, Bariatric Surgery Candidate, Obesity / overweight | BMI 35-65 | Ph 4 | Not yet recruiting | 1 | Dec 2029 | — | |
| NCT07109700A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin | Dulaglutide, HDM1005 Type 2 diabetes | HbA1c 7.5-10.5% | Ph 2 | Recruiting | 1 | Jan 2026 | — | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| NCT07276763Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention | Dulaglutide, Semaglutide Perioperative / gastric aspiration risk | — | — | Not yet recruiting | 1 | Dec 2025 | — | |
| RADIANTRole of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis | Dulaglutide Cardiovascular disease, Stroke | — | Ph 2/3 | Recruiting | 1 | Dec 2030 | — | |
| ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Jul 2027 | 15 | |
| BetaBeta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | BMI 23-45 | Ph 4 | Active, not recruiting | 1 | Dec 2027 | 11 | |
| INTERCEPTINcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Active, not recruiting | 1 | May 2026 | — | |
| NCT07417631Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. | Dulaglutide Type 2 diabetes | BMI ≥23 | — | Active, not recruiting | 1 | Mar 2026 | — | |
| NCT07619495Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk | Dulaglutide, Semaglutide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Active, not recruiting | 1 | Jun 2026 | — | |
| NCT01215968A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | BMI 18.5-40 | Ph 1 | Completed | 1 | Jul 2011 | — | results |
| NCT01250834LY2189265 and Atorvastatin Interaction Study | Dulaglutide Healthy volunteers | BMI 18.5-30 | Ph 1 | Completed | 1 | Mar 2011 | 1 | results |
| NCT01300260Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose | Dulaglutide Healthy volunteers, Type 2 diabetes | BMI 19-25 | Ph 1 | Completed | 1 | Aug 2011 | — | results |
| NCT01301092A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers. | Dulaglutide Healthy volunteers | BMI 23-35 | Ph 1 | Completed | 1 | Aug 2011 | — | results |
| NCT01432938A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants | Dulaglutide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 1 | Dec 2011 | 1 | results |
| NCT01436201A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants | Dulaglutide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 1 | Nov 2011 | 1 | results |
| NCT01458210A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants | Dulaglutide Healthy volunteers | BMI 18.5-30 | Ph 1 | Completed | 1 | Feb 2012 | 1 | results |
| NCT01524770A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe | Dulaglutide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 1 | Jun 2012 | — | results |
| NCT01667900A Study of Dulaglutide in Chinese Participants | Dulaglutide Healthy volunteers, Type 2 diabetes | HbA1c 6.5-10.5% | Ph 1 | Completed | 1 | Jun 2014 | 1 | results |
| GOLDEffects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study) | Dulaglutide | — | Ph 2 | Completed | 1 | May 2019 | 2 | |
| NCT02846233Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? | Albiglutide, Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥30 | Not applicable | Completed | 1 | Dec 2018 | 3 | results |
| GATEEffects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake | Dulaglutide Healthy volunteers | — | Ph 2 | Completed | 1 | May 2017 | 1 | |
| SKIPSmoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues | Dulaglutide Alcohol / substance use | BMI 18-30 | Ph 2 | Completed | 1 | Jul 2022 | 6 | |
| NCT03315780A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes | Dulaglutide Type 2 diabetes | — | Ph 4 | Completed | 1 | Feb 2018 | 1 | results |
| NCT03363906A Study of Dulaglutide in Healthy Participants | Dulaglutide Healthy volunteers | Healthy volunteers | Ph 1 | Completed | 1 | Jun 2018 | — | results |
| NCT03444142Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes | Dulaglutide, Exenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Nov 2021 | — | |
| NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Apr 2018 | — | |
| LICAS-MREffects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging | Dulaglutide, Liraglutide, Semaglutide Type 2 diabetes | BMI ≥30 | Not applicable | Completed | 1 | Jun 2023 | 1 | |
| D-LIFTEffect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease | Dulaglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | HbA1c 7-10% | Not applicable | Completed | 1 | Jan 2020 | 12 | |
| NCT03824002Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables | Dulaglutide Type 2 diabetes | — | Ph 4 | Completed | 1 | Oct 2017 | 1 | |
| NCT04184947Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Completed | 1 | Dec 2018 | 1 | |
| NCT04189848Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc | Dulaglutide, Semaglutide Healthy volunteers, Obesity / overweight | BMI ≥25 | Ph 4 | Completed | 1 | Jan 2020 | 1 | results |
| NCT04200625Semaglutide vs Dulaglutide on Epicardial Adipose Tissue | Dulaglutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥27 | — | Completed | 1 | Dec 2019 | — | |
| NCT04387201GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response | Dulaglutide Prediabetes / glucose intolerance | BMI ≤35 | Ph 4 | Completed | 1 | Oct 2023 | — | results |
| NCT04466904Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM | Dulaglutide, Mazdutide Type 2 diabetes | BMI ≤35 | Ph 1/2 | Completed | 1 | May 2021 | 1 | |
| NCT04829903Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin | Dulaglutide, Liraglutide Obesity / overweight, Type 2 diabetes | — | Not applicable | Completed | 1 | Mar 2021 | — | |
| NCT04876027GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS) | Dulaglutide, GLP-1 / incretin class catch-all Obesity / overweight, PCOS | BMI ≥24 | Ph 4 | Completed | 1 | Apr 2022 | — | |
| NCT04965506A Study of IBI362 in Chinese Patients With Type 2 Diabetes | Dulaglutide, Mazdutide Type 2 diabetes | HbA1c 7-10.5% | Ph 2 | Completed | 1 | Apr 2022 | 1 | |
| NCT05218915Basal Plus GLP1-ra on Glycemic Variability in CKD | Dulaglutide Chronic kidney disease, Type 2 diabetes | BMI 18-40 | Ph 4 | Completed | 1 | Oct 2024 | — | |
| GLIMPEffects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease | Dulaglutide Chronic kidney disease, Obesity / overweight | eGFR 15-59 | Ph 2 | Completed | 1 | May 2024 | — | results |
| NCT05459285A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects | Dulaglutide Healthy volunteers | Male · Healthy volunteers | Ph 1 | Completed | 1 | Jul 2022 | 10 | |
| KML002Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes | Dulaglutide Type 1 diabetes | BMI 19-34.9 | Ph 2 | Suspended | 1 | Jun 2028 | 58 | |
| NCT05492305Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Type 2 diabetes | — | — | Unknown | 1 | Jun 2023 | — | |
| NCT05606913A Study of IBI362 in Participants With Type 2 Diabetes | Dulaglutide, Mazdutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 1 | Jan 2024 | 1 | |
| NCT05680129A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM | Dulaglutide, Ecnoglutide (XW003) Type 2 diabetes | BMI 20-35 | Ph 3 | Completed | 1 | Jul 2024 | 1 | |
| NCT05990374Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years | Dulaglutide, Semaglutide, Tirzepatide Obesity / overweight, Type 2 diabetes | BMI ≥24 | Not applicable | Unknown | 1 | Jan 2024 | 1 | |
| NCT06120556Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Oct 2023 | 3 | |
| NCT06182891Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy | Dulaglutide Chronic kidney disease, Type 2 diabetes | UACR ≥30 | Not applicable | Completed | 1 | Jun 2023 | 1 | |
| NCT06331286The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity | Dulaglutide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥28 | Not applicable | Unknown | 1 | Dec 2024 | — | |
| RESIDUALResidual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery | Dulaglutide, Semaglutide Perioperative / gastric aspiration risk | — | — | Completed | 1 | Feb 2025 | — | |
| NCT06779929Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | Established ASCVD | — | Completed | 1 | Dec 2025 | 1 | |
| NCT06901648A Study of HS-20094 in Patients With T2DM | Dulaglutide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≥22 | Ph 2 | Completed | 1 | Mar 2025 | — | |
| DUP-SURPASSPrediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data | Dulaglutide, Tirzepatide Cardiovascular disease, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Jul 2025 | 1 | |
| TIRZSEMA-CVOTComparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | Dulaglutide, Semaglutide, Tirzepatide Cardiovascular disease, Obesity / overweight, Type 2 diabetes | BMI ≥25 | — | Completed | 1 | Jul 2025 | 1 | |
| DIVEEffect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes | Dulaglutide Type 2 diabetes | — | — | Completed | 1 | Jan 2021 | — | |
| DESIREEffects of Glucagon-Like Peptide-1 Analogs on Sexuality | Dulaglutide Healthy volunteers | BMI 18.5-25 | Ph 2 | Completed | 1 | Sep 2022 | — | |
| NCT04893148Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes | Dulaglutide, Lixisenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Dec 2021 | — | |
| NCT05348122A Study of TG103 Injection in Type 2 Diabetes Subjects | Dulaglutide, TG103 Type 2 diabetes | BMI ≤40 | Ph 2 | Unknown | 1 | Nov 2023 | — | |
| NCT05407961A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Macupatide Type 2 diabetes | BMI 23-45 | Ph 1 | Completed | 1 | Jan 2024 | — | |
| NCT05516966Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus | Dulaglutide, HRS9531 Type 2 diabetes | HbA1c ≤10.5% | Ph 1 | Completed | 1 | May 2023 | — | |
| NAMELS-18Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18) | Dulaglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | — | — | Completed | 1 | May 2021 | — | |
| NCT06235086A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus | Dulaglutide, TG103 Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 1 | Feb 2026 | — | |
| GBGTA Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus | Dulaglutide Perioperative / gastric aspiration risk, Type 2 diabetes | HbA1c ≥6.5% | Ph 1 | Active, not recruiting | 1 | Aug 2026 | — | |
| NCT07370922Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia | Dulaglutide Diabetes (other / unspecified) | — | Ph 2 | Completed | 1 | Nov 2025 | — | |
| NCT07537088Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | Dulaglutide Chronic kidney disease, Type 2 diabetes | BMI 21-45 | Ph 4 | Not yet recruiting | 0 | Apr 2027 | — | |
| NCT05140694Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D | Dulaglutide MASH / NAFLD / liver fibrosis, Type 2 diabetes | BMI ≥23 | Ph 4 | Unknown | 0 | Jun 2024 | — | |
| NCT03962010A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus | Dulaglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Unknown | 0 | Jun 2022 | — | |
